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Background: Long-term administration of macrolide
antibiotics  is  recognized  to  be  able  to  favorably
modify  the  clinical  condition  of  inflammatory  dis-
eases,  such  as  diffuse  panbronchiolitis  and  cystic
fibrosis. However, the precise mechanisms by which
macrolide  antibiotics  could  improve  clinical  condi-
tions of the patients are not well understood.
Aim: The present study was designed to examine the
influence  of  macrolide  antibiotics  on  effector  cell
functions responsible for inflammation through the
choice of roxithromycin (RXM) and mast cell.
Methods: Mast cells were induced by long-term cul-
ture  of  splenocytes  from  BALB/c  mice.  RXM  was
added to the cultures at seeding and then every 4Ð5
days, when the culture medium was replaced with a
fresh one. The influence of RXM on mast cell growth
was evaluated by counting the number of cells grown
on the 16th day. We also examined the influence of
RXM on mast cell activation by examining histamine
release and inflammatory cytokine secretion.
Results and conclusion: RXM could not inhibit mast
cell growth, even when splenocytes were exposed to
100 m g/ml  of  RXM  throughout  the  entire  culture
periods.  RXM  also  could  not  suppress  histamine
release from cultured mast cells in response to non-
immunological  and  immunological  stimulations.
However,  RXM  could  suppress  inflammatory  cyto-
kine, interleukin-1b , interleukin-6, granulocyte mac-
rophage-colony stimulating factor and tumor necro-
sis  factor-a ,  secretions  induced  by  concanavalin  A
stimulation at a concentration of as little as 0.5 m g/ml.
These results  may  suggest  that  RXM  modulated the
ability of mast cells to secrete inflammatory cytokines
and results in improvement of clinical  condition of
chronic inflammatory diseases.
Key  words:  Roxithromycin,  Mast  cell  growth,  In  vitro,
Mouse  splenocytes,  Inflammatory  cytokines,  IL-1b,  IL-6,
TNF-a, GM-CSF, Inhibition
Introduction
Sinobronchial syndrome involves the coexistence of
chronic  rhinosinusitis  and  chronic  lower  airway
inflammation such as chronic bronchitis and diffuse
panbronchiolitis.  Although  these  diseases  are  well
recognized  to  be  resistant  against  several  types  of
treatment,  we  use  macrolide  antibiotics,  and  sat-
isfactory results are obtained when the patients are
given  the  agents  in  one-half  the  recommended
therapeutic  doses  for  more  than  3  months.1 The
efficacy of this macrolide therapy on the inflamma-
tory diseases is generally believed to be due to their
anti-inflammatory effects,2,3 but  the precise mecha-
nisms are not well defined.
Histopathological  observations have  revealed  the
accumulation  and  activation  of  inflammatory  cells,
eosinophils  and  neutrophils  in  local  inflammatory
reactions. There is an established concept that these
inflammatory cells produce several types of chemical
mediators  (e.g.  histamine  and  serotonin)  that  are
harmful to tissue and responsible for the modification
of inflammatory responses.4,5 Inflammatory cytokines
such  as  interleukin  (IL)-1b,  IL-4,  IL-6  and  tumor
necrosis factor-a (TNF-a) are also generally believed to
function in the regulation of inflammatory responses
as one of the final effector molecules.6,7A lot of reports
clearly showed that roxithromycin (RXM), a macrolide
antibiotic,  strongly  inhibits  inflammatory  cytokine
production from T cells and macrophages in vitro and
in vivo.8,9 It is also reported that erythromycin (EM)
caused a reduction in  neutrophil  functions  such as
chemotaxis and free oxygen radical production.10,11
These reports may suggest that the inhibitory action of
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production  and  inflammatory  cell  functions  con-
stitutes  a  possible  mechanism  of  action that could
explain  the  beneficial  effects  of  the  agents  on
inflammatory diseases.
Tissue mast cells and circulating basophils are well
known to be one of the effector cells in inflammatory
responses  through  their  immunoglobulin  E  (IgE)-
dependent release of chemical mediators. It is also
reported  that  mast  cells  can  secrete  inflammatory
cytokines such as IL-4, IL-6 and TNF-a in response to
immunological and non-immunological stimulations,
and contribute to the development of inflammatory
diseases.12–14 However, the effect of macrolide anti-
biotics on mast cell functions are poorly understood.
In  the  present  study,  therefore,  we  examined  the
influence  of  macrolide  antibiotics  on  mast  cell
functions  using  RXM  and  in  vitro cell  culture
technique.
Materials and methods
Mice
BALB/c male mice, 7 weeks of age, were purchased
from Charles River Japan Inc. (Atsugi, Japan).
Conditioned medium
Conditioned medium of WEHI-3 cells containing IL-3
was obtained by  the  culture  of  2 ´ 105 cells/ml  of
WEHI-3 cells (donated from Riken Cell Bank, Tsukuba,
Japan) at 37°C in a humidified atmosphere with 5%
CO2 in  air  for  72h  in  RPMI-1640  medium  (Flow
Laboratories,  North  Ride,  Australia)  supplemented
with 10% fetal calf serum (Flow Lab), 5 ´ 10–5 M 2ME,
20 mM HEPES, 100U/ml of penicillin and 100mg/ml
of streptomycin (RPMI).
Drugs
RXM  was  kindly  supplied  by  Aventis  Pharm  Co.,
Ltd.  (Tokyo,  Japan) as  a  water-insoluble  pure  pow-
der. The  agent  was  dissolved  in  methyl  alcohol  at
20.0mg/ml  and diluted with RPMI, so as to give  a
concentration of  1.0mg/ml. This solution was then
filtered  through  a  0.22-mm  filter  (Nihon  Millipore
Corp.,  Yonezawa,  Japan)  and  stored  at  4°C  as  a
stock solution. All dilutions used in this study were
prepared from  this  stock solution  by  diluting  with
RPMI  containing  50%  conditioned  medium
(Complete  Medium).  Murine  recombinant  inter-
feron-g (IFN-g)  (specific  activity,  1.9  ´ 106 U/ml)
was kindly  provided by Tray Industries, Inc. (Kana-
gawa,  Japan),  and  used  as  a  mast  cell  growth
inhibitor.15
Cell preparation and cell culture
Spleen  cell  suspension  was  prepared  as  described
previously.8 The cells were adjusted to 10 ´ 106 cells/
ml  in  Complete  Medium.  The  cells  (1.0ml)  were
incubated  in  24-well  cluster  plates  (NUNC,  Inc.,
Naperville, IL, USA) at 37°C in a humidified atmos-
phere with 5% CO2 in the presence or absence of the
agents  in  a  total  volume  of  2.0ml.  One-half  of  the
culture medium was changed every 4–5 days.
Treatment of cells with agents
RXM was added to the cells at seeding and then every
4–5  days,  when  the  culture  medium  was  replaced
with  fresh  medium. To  study  the  effect  of  RXM  at
different stages of the cells, another series of experi-
ments was carried out, in which addition of RXM to
the cultures at seeding and 10 days after seeding were
compared. INF-g was also added to the cultures in a
similar manner.
Cell counts
The growth of the cells was measured by counting
cells in a hemocytometer. Cell viability was checked
by  trypan  blue  dye  exclusion.  Mast  cells  were
counting  according  to  the  methods  described  by
Gilbert and Ornstain.16 Each result is expressed as the
mean value ± SE  of six determinations in  triplicate
cultures.
Mast cell separation
Cultured mast cells were separated from dead cells
and  small  lymphocytes  by  Histopaque-1077  (Sigma
Chemicals,  St.  Louis,  MO,  USA)  density  gradient
centrifugation. Cultured cells were collected on day
16 and washed three times with serum-free RPMI. The
cells were re-suspended in the fresh medium, layered
on Histopaque-1077 and centrifuged at 1500r.p.m. for
10min at 25°C. Separated cells were then collected
and  re-suspended in  Complete Medium.  More  than
98%  of  separated  cells  were  stained  following  the
method of Gilbert and Ornstain.16
Histamine release from cultured mast cells
Cultured  mast  cells  were  suspended in  Hank’s  bal-
anced salt solution (HBSS) at a concentration of 5 ´
105 cells  in  the  presence  or  absence  of  various
concentrations of RXM. The cells were then stimu-
lated with either 10.0mg/ml of compound 48/80 or
1.0mg/ml of calcium ionophore A23187 at 37°C for
30min. The reaction was terminated by chilling the
tubes  in  an  ice  bath.17 After  centrifugation  at
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collected. The pelleted cells were then re-suspended
in  HBSS  and  sonically  disrupted  to  extract  residual
histamine.  Histamine  contents  were  measured  by
commercially  available  histamine  enzyme-linked
immunosorbent  assay  (ELISA)  test  kits  (IBL  GmbH,
Hamburg, Germany) according to the manufacturer’s
recommended procedure. The results were expressed
as  the  mean  percentage  inhibition  of  histamine
release ± SE of five determinations. In examining the
influence  of RXM on immunologic  release of  hista-
mine,  cultured  mast cells were suspended in  HBSS
that contained various concentrations of  RXM. The
cells were sensitized with 10.0mg/ml of mouse IgE
(Yamasa Co. Ltd., Chiba, Japan) for 60min at 37°C,
and washed three times with HBSS containing various
concentrations of RXM. The sensitized cells were then
treated  with  anti-mouse  IgE  monoclonal  antibody
(Nordic  Immunological  Lab.,  Tilburg,  The  Nether-
lands) at 37°C for  30min.17 The subsequent  proce-
dures  were  the  same  as  those  carried  out  after
addition of compound 48/80 or calcium  ionophore
A23187.
Production of cytokines from cultured mast
cells
Separated mast cells (2 ´ 106 cells/ml) were placed in
triplicate  in  24-well  cluster  plates  (NUNC)  that
contained various concentrations of  the agents and
2.5mg/ml of concanavalin A (Con A) (Sigma Chem-
icals)  in  a  final  volume  of  2.0ml. The  plates  were
maintained at 37°C in a humidified atmosphere of 5%
CO2 in  air  for  24h.  Culture  supernatants  were
obtained  after  pelleting  cells  by  centrifugation  at
3000r.p.m.  for 10min  at 4°C, and stored at  –40°C
until use.
Measurement of cytokines
IL-1b,  IL-6,  TNF-a,  and  granulocyte  macrophage-
colony stimulating factor activities in culture super-
natants were assayed using the commercially available
mouse  cytokine  ELISA Test  Kits  (Genzyme/Techne
Corp., Cambridge, MA, USA). The ELISA was carried
out  in  duplicate  according  to  the  manufacturer’s
protocol. The sensitivity of each ELISA kit is IL-1b <
10pg/ml,  IL-6  <  15pg/ml, TNF-a <  10pg/ml,  and
granulocyte macrophage-colony stimulating factor <
5pg/ml.
Statistical analysis
Statistical differences between the two groups were
evaluated  by  analysis  of  variance  combined  with
Fisher’s PLSD test.
Results
Influence of RXM on mast cell growth in vitro
The first set of experiments was designed to exam-
ine the influence of RXM on mast cell growth from
mouse  splenocytes  in  vitro. We first  examined the
kinetics  of  mast  cells  growth  from  mouse  spleno-
cytes. As shown in Fig. 1, the number of mast cells
gradually  increased,  peaked  on  the  16th  day  and
declined thereafter. We next examined the influence
of  RXM  on  mast  cell  growth. To  do  this,  10.0  or
100.0 mg/ml  of  RXM  were  added  to  the  cells  at
seeding and then every 4–5 days, when the culture
medium  was  replaced  with  a  fresh  one. The  mast
cell  numbers were counted on day 16. RXM could
not inhibit mast cell growth from splenocytes even
when  splenocytes  were  exposed  throughout  the
entire culture  period to RXM:  the number  of  mast
cells observed in cultures containing 100.0mg/ml of
RXM was quite similar (not significant, p > 0.05) to
that in  control cultures  (Fig.  2A).  On  the  contrary,
IFN-g (a  mast  cell  growth  inhibitor)  showed  a
suppressive effect on mast cells growth when sple-
nocytes  were  exposed  to  IFN-g at  more  than
100U/ml (Fig. 2B).
We next examined the effects of RXM at different
stages of mast cell growth. To accomplish this, 10.0
and 100.0mg/ml of RXM was added to the cultures 10
days after seeding, and the mast cell numbers were
counted on the 16th day. The data in Fig. 3A show that
RXM could not suppress mast cell growth even when
100.0 mg/ml of RXM was added to the cultures. This
negative suppression of mast cells growth was also
observed in cultures that received IFN-g on day 10
(Fig. 3B).
Influence of RXM on histamine release from
cultured mast cells
The second sets of experiments was carried out to
examine the influence of RXM on histamine release
from cultured mast cells. As shown in Fig. 4A, RXM
could not inhibit histamine release from mast cells in
response  to  chemical  substance  (compound  48/80
and  calcium  ionophore A23187)  stimulations. This
negative inhibitory action of RXM was also observed
when  the  cells  were  stimulated  immunologically
using  mouse  IgE  and anti-mouse IgE  (Fig.  4A). The
data  in  Fig.  4B  show  that  IFN-g could  not  inhibit
histamine release from  mast cells as in the case of
RXM.
Influence of RXM on cytokine secretion from
cultured mast cells
The  third  experiments  were  designed  to  examine
whether RXM could inhibit cytokine secretion from
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tion. As shown in Fig. 5, RXM caused a reduction in
cytokine  secretion. This  suppression  was  observed
when the  cells  were stimulated with Con A in  the
presence  of  RXM  at  a  concentration of  as  little  as
0.5mg/ml.
Discussion
Long-term administration (for more than 3 months) of
macrolide antibiotics is reported to favorably modify
the clinical status of inflammatory disorders such as
diffuse panbronchiolitis, asthma and chronic rhinosi-
nusitis.1 Furthermore, this macrolide therapy is used
for the treatment of cystic fibrosis, which is the most
common autosomal recessive disorder in Caucasians,
and it has been reported that there was a significant
improvement  in  lung  functions  following  treat-
ment.18,19 Although these reports may  suggest  that
macrolide  therapy  is  recognized  as  one  available
treatment  for  chronic  inflammatory  diseases,  the
precise mechanisms by which macrolide antibiotics
could improve clinical conditions of the patients are
not well defined.
It  is  well  known  that  there  are  several  distinct
inflammatory pathways, each of which proceeds via a
cascade of biological events.20 Many of the individual
steps in the inflammatory cascade are controlled by
soluble factors such as histamine and serotonin that
are secreted mainly from mast cells and eosinophils,
so-called final effector cells.20 Yet the action of RXM
on  these  effector  cell  functions  is  not  well  under-
stood. To examine the influence of RXM on effector
cell functions we chose mast cells, and first tested cell
growth using an in vitro cell culture technique. The
present  results  clearly  show  that  RXM  could  not
suppress  mast  cell  growth  from  normal  mouse
splenocytes.  Furthermore,  this  negative  inhibitory
effect of RXM on mast cell growth is also observed
when the agent was added to cultures on day 10. Mast
cells are reported to be derived from precursors that
originated in  the  bone  marrow  and  then  reside in
blood,  peripheral  mucosa  and  peripheral  tissues
including  spleen  and  lymph  nodes.21 It  is  also
recognized that inflammatory responses in these sites
bring  about differentiation and proliferation of  pre-
cursors and matured mast cells, and result in accumu-
lation of numerous mast cells.21 Together with these
reports, the present results clearly  show that RXM,
T. Shimane et al.
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FIG. 1. Mast cell induction in cultured murine splenocytes. Spleen cells (1 ´ 10
7 cells/ml) were cultured, and the culture medium
was replaced with the fresh one every 4–5 days. Mast cells were counted when the culture medium was replaced. Each point
represents the mean ± SE from six determinations in triplicate cultures.Macrolide antibiotic and mast cell growth
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.different from IFN-g, does not exert harmful effects
on mast cell precursors and mature mast cells. It is
also reasonable to speculate that the present results
may be interpreted that RXM does not interfere with
differentiation  and  proliferation  of  mast  cells  even
when  the  agent  is  administered  into  patients with
chronic  inflammatory  diseases  for  a  long  period
(more than 3 months).
We  next  examined  the  influence  of  RXM  on
mediator release from cultured mast cells. As shown
in  Fig.  4,  RXM  could  not  inhibit  histamine  release
even when the cells were stimulated in the presence
of  100mg/ml  of  RXM.  EM  prevents  calcium  influx
into cells,22 resulting in reduced permeability of the
cell  membrane  and  inhibition  of  histamine  release
from  mast  cells  in  response  to  non-immunological
and immunological stimulations. It is also observed
that EM increases the content of intracellular cyclic
adenosine  monophosphate (cAMP),23 which  elabo-
rates  an  important  downregulatory  signal  in  the
release  of  mediators  synthesized  in  cytosol.24,25
From these reports, it is possible that RXM prevents
accumulation  of  calcium  cation  in  the  cytosol  and
enhances  the  intracellular  cAMP  level,  resulting  in
inhibition of histamine secretion.
Inflammatory cells, including mast cells, are repor-
ted to secrete not only chemical mediators, but also
several  types  of  inflammatory  cytokines,  and  to
control  the  development  of  inflammatory  respon-
ses.26 Therefore, we finally examined whether RXM
could  suppress  inflammatory  cytokine  production
from  mast  cells.  As  shown  in  Fig.  5,  RXM  exerts
suppressive  effects  on  inflammatory  cytokine  pro-
duction  from  mast  cells  in  response  to  Con  A
stimulation in vitro. It is reported that EM and RXM
inhibit  inflammatory  cytokine  production  from  T
cells  and  macrophages  through  the  inhibition  of
mRNA expression.27 EM  has  also  been  reported to
suppress  IL-8  mRNA  expression  and  activation  of
both  nuclear  factor-kB  and  activator  protein-1  in
bronchial  epithelial  cells.28,29 Taken  together,  the
present  results  may  be  interpreted  such  that  RXM
inhibits  both  inflammatory  cytokine mRNA  expres-
sion  and  activation  of  transcription  factors,  and
results  in  inhibition  of  inflammatory  cytokine
productions.
Given the importance of  cytokines in  the patho-
genesis of inflammatory disorders4 and the observa-
tion  that  mast  cells  are  an  important  source  of
several  inflammatory  cytokines,12–14 the  present
results  may  suggest  that  treatments  which  target
cytokine secretion from mast cells may be useful in
the control of inflammatory diseases. This suggestion
may be supported by the observation that corticos-
teriods and FK-506,  which have no ability to inter-
fere with chemical mediator release from mast cells,
could favorably modify the clinical status of diseases
by  inhibition  of  inflammatory  cytokine  secretion
from mast cells in vivo.30,31 Furthermore, the pres-
ent results  suggest  the possibility  that some of  the
therapeutic effects of RXM on inflammatory diseases
depends on their ability  to reduce the secretion of
inflammatory  cytokines  from  mast  cells  as  well  as
mononuclear  leukocytes  such  as  T  cells  and
macrophages.
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